In the context of IBD, treatment with several IL-17 neutralising antibodies has been shown to have limited efficacy with some patients completely refractory to treatment.39 In a proof-of-concept experiment, Ab-IPL-IL-17 was able to deplete/sequester plasma IL-17A within samples obtained from treatment naïve patients with IBD attending an inception clinic (figure 5G) but had no effect on plasma IL-6 or TNF-α concentrations (online supplemental figure S11). This evidence concerns the gene IL17A and inflammatory bowel disease.